Castle Creek Biosciences, Inc.

Castle Creek Biosciences is a late-stage biotechnology company focused on developing re-dosable gene therapies for patients with rare, genetic diseases. They have a strong commitment to life science innovation and are a portfolio company of Paragon Biosciences, a global life science leader that invests in innovative biology-based companies. Castle Creek's primary focus is on developing therapies for skin and connective tissue disorders, with their lead candidate, D-Fi, being a gene therapy for dystrophic epidermolysis bullosa (DEB).

Castle Creek Biosciences boasts a robust pipeline of disease-modifying therapies and a distinctive approach that emphasizes personalized, targeted, and re-dosable cell-based treatments. They have a dedicated team of experts, including a passionate leadership team with significant experience in the cell and gene therapy fields. The company prioritizes collaboration with patient advocates and advocacy organizations, providing valuable resources and support to the patient community.

Castle Creek Biosciences offers a flexible work environment for their employees, providing a competitive base salary, annual bonuses, and a comprehensive benefits package that includes medical, dental, and vision coverage, a 401K savings plan, short and long-term disability insurance, and paid vacation and annual holidays.

Castle Creek Biosciences offers a comprehensive benefits package to its full-time employees, including medical, dental, and vision coverage, a 401K savings plan, short and long term disability insurance, paid vacation and annual holidays, and a competitive base salary with an annual bonus. The company values its employees and offers opportunities for professional development and advancement.

Castle Creek Biosciences is a late-stage company dedicated to developing transformative therapies for patients with genetic diseases. Focused on creating re-dosable gene therapies, they are committed to improving the lives of people living with these conditions, particularly those with dystrophic epidermolysis bullosa (DEB), a genetic skin disorder with limited treatment options.

Castle Creek Biosciences emphasizes a culture of innovation and dedication to improving the lives of patients with genetic diseases. They are a late-stage company with a focus on developing re-dosable gene therapies, and they value their employees, providing opportunities for professional development and advancement. The company offers a competitive salary and benefits package, and their headquarters is located in a convenient and amenity-rich area. This combination creates a supportive and rewarding work environment where employees can contribute to making a real difference in the lives of others.

Castle Creek Biosciences is an Equal Opportunity Employer, committed to fostering a diverse, equitable, and inclusive workplace. They are focused on building a company culture that values all individuals and provides opportunities for professional development and advancement for all employees. The company emphasizes creating an inclusive environment where everyone feels respected, valued, and empowered to contribute their unique perspectives and talents.